Dirk Schadendorf, MD, discusses expected toxicities with the combination of encorafenib, binimetinib, and pembrolizumab in BRAF V600E/K-mutated melanoma.
Dirk Schadendorf, MD, Essen University Hospital
Advertisement
Articles by Dirk Schadendorf, MD, Essen University Hospital
Advertisement
Latest Updated Articles
Ipilimumab Dosing Significance in Adjuvant SettingOctober 12th 2020
Immune Checkpoint Inhibition in Stage IV MelanomaOctober 12th 2020
Triple Therapy for the Management of MelanomaOctober 12th 2020
COMBI-AD Trial 5-Year Analysis DataOctober 12th 2020
COMBI-i Trial Data UpdatesOctober 12th 2020
Checkpoint Blockade Trial Data UpdatesOctober 12th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
FDA Awards Orphan Drug Designation to Enzomenib for ALL
4
Dr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer
5